^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-08046054

    i
    Other names: PF-08046054, SGN-PDL1V, PF08046054, SGNPDL1V, PF 08046054, SGN PDL1V
    Company:
    Pfizer
    Drug class:
    Microtubule inhibitor, PD-L1-targeted antibody-drug conjugate
    Related drugs:
    2ms
    SGNPDL1V-001: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=438, Recruiting, Seagen Inc. | Trial completion date: Dec 2026 --> Dec 2027
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PF-08046054
    3ms
    SGNPDL1V-001: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=438, Recruiting, Seagen Inc. | N=322 --> 438
    Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • PF-08046054
    over2years
    Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress). (ASCO 2022)
    Objective response rate will be analyzed by tumor type, dose levels, and schedules. Enrollment for Part A is ongoing at sites in North America and is planned in Europe.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PF-08046054